Chelsea Therapeutics International (CHTP) 4.73 $CHTP
Impax Breathes New Life Into Stalled Parkinson's Drug
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors had high hopes when Impax filed for FDA approval of IPX066, or Rytary, an extended release version of a common Parkinson's drug therapy, in 2011. But manufacturing woes dashed the drug's chances for an FDA approval, and ultimately...
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
13.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Wed Apr 02, 9:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 3 months, Chelsea Therapeutics International has returned 13.91% as of today's recent price of $5.73.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
Shares of CHTP Up 21.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 21, 5:04PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 21.27% as of today's recent price of $6.10.
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
As more key drugs come off of patent protection, one of the central themes in biotech this year is the buyout. Companies like AstraZeneca plc and Eli Lilly , that have been deeply stricken by the so-called patent cliff, will undoubtedly be on the...
Technical Commentary on Most Active Equities: Chelsea Therapeutics Intl., Hewlett-Packard, JetBlue Airways, and American Realty Capital Properties
PR Newswire - Fri Mar 14, 7:53AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Chelsea Therapeutics International Ltd (NASDAQ:CHTP), Hewlett-Packard Co. (NYSE:HPQ), JetBlue Airways Corp. (NASDAQ:JBLU), and American Realty Capital Properties Inc. (NASDAQ:ARCP). Free research on these four companies can be accessed at:
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Impax Breathes New Life Into Stalled Parkinson's Drug
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors had high hopes when Impax filed for FDA approval of IPX066, or Rytary, an extended release version of a common Parkinson's drug therapy, in 2011. But manufacturing woes dashed the drug's chances for an FDA approval, and ultimately...
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free
13.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Wed Apr 02, 9:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 3 months, Chelsea Therapeutics International has returned 13.91% as of today's recent price of $5.73.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
Shares of CHTP Up 21.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 21, 5:04PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 21.27% as of today's recent price of $6.10.
Agreements, Financial Results, Clinical Study Results, Debt Financing, and Drug Application Updates - Analyst Notes on Tesaro, Chelsea Therapeutics, Venaxis, Geron, and Unilife
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Venaxis, Inc. (NASDAQ: APPY), Geron Corporation (NASDAQ: GERN), and Unilife Corporation (NASDAQ: UNIS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
As more key drugs come off of patent protection, one of the central themes in biotech this year is the buyout. Companies like AstraZeneca plc and Eli Lilly , that have been deeply stricken by the so-called patent cliff, will undoubtedly be on the...
Technical Commentary on Most Active Equities: Chelsea Therapeutics Intl., Hewlett-Packard, JetBlue Airways, and American Realty Capital Properties
PR Newswire - Fri Mar 14, 7:53AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Chelsea Therapeutics International Ltd (NASDAQ:CHTP), Hewlett-Packard Co. (NYSE:HPQ), JetBlue Airways Corp. (NASDAQ:JBLU), and American Realty Capital Properties Inc. (NASDAQ:ARCP). Free research on these four companies can be accessed at:
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
